NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,052 | -92.1% | 20,952 | -56.0% | 0.00% | -90.9% |
| Q3 2022 | $152,000 | +1281.8% | 47,596 | +1537.9% | 0.01% | +1000.0% |
| Q2 2022 | $11,000 | +1000.0% | 2,906 | +1353.0% | 0.00% | – |
| Q1 2022 | $1,000 | -92.9% | 200 | -74.9% | 0.00% | -100.0% |
| Q3 2021 | $14,000 | -60.0% | 797 | -47.8% | 0.00% | -80.0% |
| Q2 2020 | $35,000 | -82.7% | 1,528 | -83.7% | 0.01% | -75.0% |
| Q4 2019 | $202,000 | -76.8% | 9,363 | -47.4% | 0.02% | -66.1% |
| Q2 2018 | $869,000 | +219.5% | 17,813 | +12.2% | 0.06% | +96.7% |
| Q3 2016 | $272,000 | -62.7% | 15,882 | -73.7% | 0.03% | -70.0% |
| Q3 2014 | $729,000 | +40.2% | 60,448 | +48.8% | 0.10% | +22.0% |
| Q2 2014 | $520,000 | +51900.0% | 40,637 | +40537.0% | 0.08% | – |
| Q4 2013 | $1,000 | -97.9% | 100 | -97.8% | 0.00% | -100.0% |
| Q3 2013 | $48,000 | – | 4,600 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |